R
Roman Gulati
Researcher at Fred Hutchinson Cancer Research Center
Publications - 137
Citations - 6512
Roman Gulati is an academic researcher from Fred Hutchinson Cancer Research Center. The author has contributed to research in topics: Prostate cancer & Population. The author has an hindex of 37, co-authored 115 publications receiving 5183 citations. Previous affiliations of Roman Gulati include University of Washington & Veterans Health Administration.
Papers
More filters
Journal ArticleDOI
Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer
Colin C. Pritchard,Joaquin Mateo,Michael Walsh,Navonil De Sarkar,Wassim Abida,Himisha Beltran,Andrea Garofalo,Roman Gulati,Suzanne Carreira,Rosalind A. Eeles,Olivier Elemento,Mark A. Rubin,Dan R. Robinson,Robert J. Lonigro,Maha Hussain,Arul M. Chinnaiyan,Arul M. Chinnaiyan,Jake Vinson,Julie Filipenko,Levi A. Garraway,Mary-Ellen Taplin,Saud H. AlDubayan,G. Celine Han,Mallory Beightol,Colm Morrissey,Belinda Nghiem,Heather H. Cheng,Bruce Montgomery,Tom Walsh,Silvia Casadei,Silvia Casadei,Michael F. Berger,Liying Zhang,Ahmet Zehir,Joseph Vijai,Howard I. Scher,Charles L. Sawyers,Nikolaus Schultz,Philip W. Kantoff,David B. Solit,Mark E. Robson,Eliezer M. Van Allen,Kenneth Offit,Johann S. de Bono,Peter S. Nelson,Peter S. Nelson +45 more
TL;DR: The frequency of germline mutations in DNA-repair genes among men with metastatic prostate cancer significantly exceeded the prevalence of 4.6% among 499 men with localized prostate cancer and 2.7% in the Exome Aggregation Consortium, which includes 53,105 persons without a known cancer diagnosis.
Journal ArticleDOI
Lead Time and Overdiagnosis in Prostate-Specific Antigen Screening: Importance of Methods and Context
Gerrit Draisma,Ruth Etzioni,Alexander Tsodikov,Angela B. Mariotto,Elisabeth M. Wever,Roman Gulati,Eric J. Feuer,Harry J. de Koning +7 more
TL;DR: Three independently developed mathematical models of prostate cancer progression and detection were used to estimate lead times and the fraction of overdiagnosed cancers due to PSA screening among US men aged 54-80 years in 1985-2000.
Journal ArticleDOI
Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer
Akash Kumar,Ilsa Coleman,Colm Morrissey,Xiaotun Zhang,Lawrence D. True,Roman Gulati,Ruth Etzioni,Hamid Bolouri,Bruce Montgomery,Thomas A. White,Jared M. Lucas,Lisha G. Brown,Ruth Dumpit,Navonil DeSarkar,Celestia S. Higano,Evan Y. Yu,Roger Coleman,Nikolaus Schultz,Min Fang,Min Fang,Paul H. Lange,Jay Shendure,Robert L. Vessella,Peter S. Nelson +23 more
TL;DR: Analysis of multiple tumors from men with disseminated prostate cancer indicates that evaluating a single metastasis provides a reasonable assessment of the major oncogenic driver alterations that are present in disseminated tumors within an individual, and thus may be useful for selecting treatments on the basis of predicted molecular vulnerabilities.
Journal ArticleDOI
Quantifying the role of PSA screening in the US prostate cancer mortality decline
Ruth Etzioni,Alexander Tsodikov,Alexander Tsodikov,Angela B. Mariotto,Aniko Szabo,Aniko Szabo,Seth Falcon,Jake Wegelin,Jake Wegelin,Dante diTommaso,Dante diTommaso,Kent Karnofski,Roman Gulati,David F. Penson,Eric J. Feuer +14 more
TL;DR: PSA screening may account for much, but not all, of the observed drop in prostate cancer mortality, and other factors, such as changing treatment practices, may also have played a role in improving prostate cancer outcomes.
Journal ArticleDOI
Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials
Alexander Tsodikov,Roman Gulati,Eveline A.M. Heijnsdijk,Paul F. Pinsky,Sue Moss,Sheng Qiu,Tiago M. de Carvalho,Jonas Hugosson,Christine D. Berg,Anssi Auvinen,Gerald L. Andriole,Monique J. Roobol,E. David Crawford,Vera Nelen,Maciej Kwiatkowski,Marco Zappa,Marcos Lujan,Arnauld Villers,Eric J. Feuer,Harry J. de Koning,Angela B. Mariotto,Ruth Etzioni +21 more
TL;DR: The objectives of this study were to formally test whether the effects of screening on prostate cancer mortality differed between the ERSPC and PLCO after differences in implementation and practice settings were accounted for and to estimate the effect of screening in both trials relative to no screening.